Policy Brief - Testeo genético de DPYD precio a fluoropirimidinas en cánceres sólidos: una política sanitaria para reducir la toxicidad grave en oncología

13 H., Tie, J., IJzerman, M., Alexander, M., & Michael, M. (2025). Cost-effectiveness of pre-emptive DPYD genotyping compared to standard of care among patients receiving fluoropyrimidine-based anti-cancer treatment in Australia. Clinical Drug Investigation, 45 (12), 945–956. https://doi.org/10.1007/s40261-025- 01489-w Gómez-Zamora, M., López-Cepero, M., Do Pazo Oubiña, F., Obrador de Hevia, A., Oliver Noguera, A., Trujillo Ruiz, A., Castro Manzanares, M., & Guillot Morales, M. (2025). Frecuencia e impacto clínico de las variantes del gen DPYD. ILAPHAR | Revista de la OFIL, 35 (4), artículo 319. https://www.ilaphar.org/frecuencia-e- impacto-clinico-de-las-variantes-del-gen-de-la-dpyd/ Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G. J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., Jeurissen, F. J. F., Portielje, J. E. A., Jansen, R. L. H., Hamberg, P., Ten Tije, A. J., Droogendijk, H. J., Koopman, M., Nieboer, P., van de Poel, M. H. W., Mandigers, C. M. P. W., Rosing, H., Beijnen, J. H., van Werkhoven, E., van Kuilenburg, A. B. P., van Schaik, R. H. N., Mathijssen, R. H. J., Swen, J. J., Gelderblom, H., Cats, A., Guchelaar, H. J., & Schellens, J. H. M. (2019). A cost analysis of upfront DPYD genotype- guided dose individualisation in fluoropyrimidine- based anticancer therapy. European Journal of Cancer, 107 , 60–67. https://doi.org/10.1016/j.ejca.2018.11.010 Ho, T. T., Smith, D. M., Aquilante, C. L., Cicali, E. J., El Rouby, N., Hertz, D. L., Imanirad, I., Patel, J. N., Scott, S. A., Swain, S. M., Tuteja, S., & Hicks, J. K. (2025). A guide for implementing DPYD genotyping for systemic fluoropyrimidines into clinical practice. Clinical Pharmacology & Therapeutics, 117 (5), 1194–1208. https://doi.org/10.1002/cpt.3567 Koleva-Kolarova, R., Vellekoop, H., Huygens, S., Versteegh, M., Mölken, M. R., Szilberhorn, L., Zelei, T., Nagy, B., Wordsworth, S., & Tsiachristas, A. (2023). Cost- effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK. Personalized Medicine, 20 (4), 339– 355. https://doi.org/10.2217/pme-2022-0099 Lunenburg, C. A. T. C., van der Wouden, C. H., Nijenhuis, M., Crommentuijn-van Rhenen, M. H., de Boer-Veger, N. J., Buunk, A. M., Houwink, E. J. F., Mulder, H., Rongen, G. A., van Schaik, R. H. N., van der Weide, J., Wilffert, B., Deneer, V. H. M., Swen, J. J., & Guchelaar, H. J. (2020). Dutch Pharmacogenetics Working Group guideline for the gene–drug interaction between DPYD and fluoropyrimidines. European Journal of Human Genetics, 28 , 508–517. https://doi.org/10.1038/s41431- 019-0540-0 Nelson, R. S., & Hertz, D. L. (2025). DPYD testing gains ground: NCCN guideline update reflects decades of work toward safer chemotherapy. Pharmacy Practice in Focus: Oncology, 7 (4). https://www.pharmacytimes . com/v i ew/dpyd- tes t i ng-ga i ns-ground-nccn- guideline-update-reflects-decades-of-work-toward- safer-chemotherapy Owen, G. I., Córdova-Delgado, M., Bustos, B. I., Cerpa, L. C., González, P., Morales-Pison, S., García-Bloj, B., Garrido, M., Miquel, J. F., & Quiñones, L. A. (2024). Assessing the occurrence and influence of cancer chemotherapy-related pharmacogenetic alleles in the Chilean population. Pharmaceutics, 16 (4), 561. https:// doi.org/10.3390/pharmaceutics16040561 Quiñones, L. A. (2025). Genotipificación del gen DPYD: Una obligación ética y legal para la protección del paciente oncológico [Genotyping of the DPYD gene: An ethical and legal obligation for the protection of the oncology patient]. Revista Médica de Chile, 153 (10), 745–747. https://doi.org/10.4067/S0034-98872025001000745 Quiñones, L. A., Martínez, M. F., Vargas, R., Cerpa, L. C., López-Cortés, A., González-Martínez, F., Fonseca, D., Duconge, J., Varela, N. M., Lares-Asseff, I., Redal, M. A., Esperón, P., Ríos-Santos, F., Rendón, A. L., Serrano, R., Ortega, E., Sullón-Dextre, L., Sanchez, E., Arias, M. L., Remírez, D., & Morales, A. (2026). Addressing genetic diversity and health inequities: RELIVAF’s proposal for Latin American pharmacogenomic guidelines. Frontiers in Pharmacology, 17, 1721828. https://doi. org/10.3389/fphar.2026.1721828 Resolución Exenta N° 1084. (2025). Modificación precios base GRD. FONASA.